We are live on ! Find out more

2,926 hedge funds and large institutions have $131B invested in Pfizer in 2023 Q3 according to their latest regulatory filings, with 126 funds opening new positions, 1,188 increasing their positions, 1,382 reducing their positions, and 207 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more funds holding in top 10

Funds holding in top 10: 5152 (+1)

0.31% less ownership

Funds ownership: 69.57%69.26% (-0.31%)

8% less call options, than puts

Call options by funds: $2.44B | Put options by funds: $2.65B

4% less funds holding

Funds holding: 3,0422,926 (-116)

10% less capital invested

Capital invested by funds: $145B → $131B (-$14.2B)

14% less repeat investments, than reductions

Existing positions increased: 1,188 | Existing positions reduced: 1,382

39% less first-time investments, than exits

New positions opened: 126 | Existing positions closed: 207

Holders
2,926
Holders Change
-116
Holders Change %
-3.81%
% of All Funds
46.43%
Holding in Top 10
52
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+1.96%
% of All Funds
0.83%
New
126
Increased
1,188
Reduced
1,382
Closed
207
Calls
$2.44B
Puts
$2.65B
Net Calls
-$210M
Net Calls Change
+$421M
Name Holding Trade Value Shares
Change
Change in
Stake
SHFA
926
SS&H Financial Advisors
Michigan
$3.17M +$3.38M +95,640 New
HCM
927
Hengehold Capital Management
Ohio
$3.17M +$81.7K +2,310 +2%
EA
928
Ellsworth Advisors
Ohio
$3.14M +$70.1K +1,981 +2%
WBC
929
Westpac Banking Corp
Australia
$3.14M +$1.58M +44,699 +90%
AA
930
Altrafin AG
$3.14M -$252K -7,126 -7%
PP
931
Patten & Patten
Tennessee
$3.12M -$59.3K -1,678 -2%
GCM
932
Gladius Capital Management
Illinois
$3.11M +$2.38M +67,349 +255%
Wealthfront Advisers
933
Wealthfront Advisers
California
$3.11M -$4.86M -137,387 -59%
GWM
934
GSB Wealth Management
Connecticut
$3.08M +$176K +4,978 +6%
DIA
935
Dana Investment Advisors
Wisconsin
$3.08M +$133K +3,751 +4%
NCM
936
Nelson Capital Management
California
$3.08M -$68.1K -1,926 -2%
PL
937
Plancorp LLC
Missouri
$3.08M +$57.6K +1,629 +2%
SFO
938
Stokes Family Office
Louisiana
$3.07M -$244K -6,906 -7%
SA
939
Shilanski & Associates
Alaska
$3.07M +$103K +2,908 +3%
CG
940
Cutler Group
California
$3.04M +$1.24M +35,198 +62%
HDIM
941
Hanson & Doremus Investment Management
Vermont
$3.01M -$32.9K -931 -1%
SGI
942
Summit Global Investments
Utah
$3M -$4.35M -123,152 -58%
SIP
943
Stoneridge Investment Partners
Pennsylvania
$2.99M +$3.19M +90,109 New
SFM
944
Sphera Funds Management
Israel
$2.99M -$1.77M -50,000 -36%
OCAM
945
Onex Canada Asset Management
Ontario, Canada
$2.98M -$488K -13,800 -13%
AC
946
Abbrea Capital
California
$2.95M -$12K -338 -0.4%
WI
947
Wahed Invest
New York
$2.95M +$294K +8,324 +10%
UH
948
Unigestion Holding
Switzerland
$2.95M -$601K -16,993 -16%
GD
949
Grandfield & Dodd
New York
$2.95M +$486K +13,756 +18%
SIA
950
Strategic Investment Advisors
Michigan
$2.94M -$104K -2,940 -3%

PFE Hedge Fund Activity: Q3 2023 in Review

2,926 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2023, worth a combined $131B — down 9.8% from $145B a quarter earlier.

Sellers outnumbered buyers: 207 funds closed out of PFE and 126 opened new positions — a net loss of 81 holders — while 1,382 trimmed existing stakes and 1,188 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $581M. The largest seller was Capital World Investors, cutting an estimated $595M.

  • 2,926 institutional investors held Pfizer (PFE) as of Q3 2023, down from 3,042 in Q2 2023.
  • Funds reported $131B of Pfizer stock for Q3 2023, down 9.8% quarter-over-quarter.
  • 126 funds opened new Pfizer positions in Q3 2023 and 207 closed out, a net change of -81 holders.
  • The largest Pfizer buyer in Q3 2023 was T. Rowe Price Associates, an estimated $581M added.
  • The largest Pfizer seller in Q3 2023 was Capital World Investors, an estimated $595M sold.

Based on aggregated 13F filings for Q3 2023.